Key Metrics for HealthTech and MedTech companies to raise a Series A, B and C round in Europe
NA
Key Metrics for a HealthTech and MedTech company to raise a Series A round in Europe in today's environment
The European healthtech and medtech sectors have entered a phase of disciplined maturity, transitioning away from the venture subsidised experimentation of the early 2020s toward an era characterised by industrialisation and regulatory Darwinism.
In the current market environment of 2025 and 2026, the criteria for a successful Series A funding round have shifted fundamentally. Investors no longer prioritise raw user acquisition or speculative growth; instead, they demand a rigorous demonstration of clinical utility, regulatory fortitude and a clear line of sight to measurable return on investment (ROI) within strained healthcare systems.
This structural transformation is driven by elevated costs of capital and the simultaneous enforcement of complex legislative frameworks, including the EU Medical Device Regulation (MDR), the In Vitro Diagnostic Regulation (IVDR), and the EU AI Act.
For a startup to secure Series A capital today, it must navigate a landscape where capital is highly polarised, concentrating in a narrow cohort of "de-risked" assets that can prove their integration into clinical pathways and their ability to alleviate systemic burdens.
Key Metrics for a HealthTech and MedTech company to raise a Series B round in Europe in today's environment
The European healthcare technology and medical technology sectors have reached a definitive inflection point in 2026, transitioning from a period of speculative experimentation into what industry analysts categorise as the era of industrial maturity. This evolution is characterised by a "flight to quality," where the market has bifurcated into a high-conviction environment for category leaders and a severe capital squeeze for mid-stage ventures that fail to demonstrate immediate, systemic value.
As the aggregate data suggests a resilient recovery, evidenced by European digital health funding rising to an estimated $6.2 Billion in 2025, the underlying mechanics of the Series B round reveal a persistent "Series B Gap," with the time to close funding rounds now approaching 10 to 12 months. Investors are no longer captivated by technological promise in isolation; instead, they prioritise deep integration into clinical workflows, robust unit economics and a transparent path to profitability.
Key Metrics for a HealthTech and MedTech company to raise a Series C round in Europe in today's environment
The European healthcare technology and medical technology landscape has entered a profound inflection point as it moves through 2025 and into 2026. This period is increasingly defined by a transition from the speculative fragmentation and "growth-at-all-costs" mindset of the early 2020s to a disciplined, professionalised era termed industrial maturity.
For companies preparing to raise a Series C funding round in this environment, the requirements have shifted from simple user acquisition or technological promise to a rigorous demonstration of unit economics, regulatory resilience, clinical validation and structural integration into healthcare systems.
The defining thesis for venture capital and private equity in 2026 is the industrialisation of the sector, where valuations are no longer detached from the realities of reimbursement and clinical outcomes. This shift is necessitated by an elevated cost of capital and a "Great Capital Polarisation" that favours de-risked category leaders over smaller, unprofitable ventures.
To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email [email protected]